Eli Lilly

Eli Lilly Accelerates Growth Strategy Through Strategic Collaborations

kashif hafeez - January 30, 2026

Eli Lilly’s Strategic Pipeline and Partnerships Drive Investor Confidence

January 20, 2026

Eli Lilly Faces Regulatory Setback for Key Obesity Drug Candidate

January 18, 2026

Eli Lilly Faces Regulatory Delay for Key Obesity Drug

angelina - January 17, 2026

Eli Lilly Faces New Challenge in Weight-Loss Drug Race

kashif hafeez - December 24, 2025

Eli Lilly Positions Oral Weight-Loss Drug as Formidable Rival to Novo Nordisk

Brett Shapiro - December 19, 2025

Eli Lilly Strengthens Obesity Portfolio with Promising Trial and Strategic Alliance

December 17, 2025

Eli Lilly Sets a New Benchmark in Weight-Loss Drug Development

Brett Shapiro - December 12, 2025

Eli Lilly Bets Billions on U.S. Expansion to Fuel Growth

kashif hafeez - December 11, 2025

Eli Lilly Strengthens Gene Therapy Ambitions with Strategic Acquisition

angelina - December 9, 2025

Eli Lilly’s Strategic Gains: Dividend Hike and China Market Access Bolster Long-Term Outlook

Brett Shapiro - December 9, 2025

Eli Lilly Gains Strategic Foothold in China with Key Reimbursement Win

Brett Shapiro - December 8, 2025

Eli Lilly Shares Face Market Correction Amid Strong Operational Performance

Brett Shapiro - December 6, 2025

Eli Lilly’s Bold Price Cut Sparks Investor Jitters

Brett Shapiro - December 1, 2025

Eli Lilly Reaches Unprecedented Market Valuation

angelina - November 27, 2025

12 Page 1 of 2